Monday, June 26, 2017 11:12:30 PM
There are two primary reasons why many of the Biotechs sitting with large amounts of NOLs do not go down the path of P10.
1. Previous Ownership Change of the Company under Section 382 (see my previous posts for more details on what constitutes an Ownership Change)
Most simplistically, in order for the Company NOLs to be used effectively (and not subject to limitations), the Company must not have undergone an Ownership Change in the past or in the process of raising capital to fund the acquisition of a profitable target.
In most cases biotech companies with undergo one or more Ownership Changes after a drug fails and larger shareholders bail out. Once this happens, it is almost impossible to remedy the NOL usage limitation.
Further, the possibility of raising the substantial capital necessary to fund an acquisition and provide that investor with enough of an equity stake to make them interested in the opportunity, will in most cases create another Ownership Change.
Why did these things work with P10? - They had no Ownership Change prior to the Bankruptcy (rare) and investment from 210 Capital fell under a Section 382 exemption which allows one Ownership Change during the process of Chapter 11 if certain conditions are met (which they were)
2. Residual Liabilities
Absent a full sale of assets and operating business with an indemnity or going thru the bankruptcy process the Company will not be clear of potential legacy liabilities and that overhang is not something large investors are typically comfortable with.
Why did these things work with P10? Thru the sale to Langley, all liabilities were assumed by Langley and P10 was fully indemnified - Further P10 went thru the bankruptcy process which further cleaned up the past.
All of that said, P10 was a unique target because it did not have a past Ownership Change, Langley assumed all past liabilities and provided an indemnification (and their indemnification has value), and it had a business reason to go thru the bankruptcy process (the Braker Facility Lease) which allowed the 210 Capital investment and also cleaned up any other potential residual liabilities. Maybe several Biotechs could fit this fact pattern, but it would not be that likely.
-BioHunter
Twitter: @TheBio_Hunter
Recent PX News
- P10 Hosts Investor Day • GlobeNewswire Inc. • 09/19/2024 11:30:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 11:03:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/17/2024 12:06:36 PM
- P10 Announces Agreement to Acquire Qualitas Funds, a Leading European Lower-Middle Market Alternative Investment Solutions Provider • GlobeNewswire Inc. • 09/17/2024 12:00:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/09/2024 12:02:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 12:00:17 PM
- P10 Reports Second Quarter 2024 Earnings Results • GlobeNewswire Inc. • 08/08/2024 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 12:33:02 PM
- P10 Expands Credit Agreement to $500 Million • GlobeNewswire Inc. • 08/05/2024 12:30:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/02/2024 04:15:14 AM
- P10 Names Sarita Narson Jairath as EVP and Global Head of Client Solutions • GlobeNewswire Inc. • 07/31/2024 08:15:50 PM
- P10 to Host Investor Day on September 19, 2024 • GlobeNewswire Inc. • 07/23/2024 08:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/19/2024 08:16:43 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/19/2024 08:10:55 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/19/2024 08:05:26 PM
- P10 Schedules Second Quarter 2024 Earnings Release for Thursday, August 8, 2024 • GlobeNewswire Inc. • 07/18/2024 12:30:33 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/12/2024 09:31:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2024 10:37:57 PM
- Hark Capital Closes on $645 Million in Capital Commitments for Fund IV • GlobeNewswire Inc. • 07/09/2024 12:30:00 PM
- RCP Advisors Announces Launch of New Website and Brand • GlobeNewswire Inc. • 07/01/2024 12:30:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 12:49:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 12:48:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 12:45:20 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM